In internationally comparative terms, the Greek healthcare system appears to be both efficient and effective measured in terms of life expectancy at birth, but it does not enjoy the confidence of its users.
There has been a significant reduction in healthcare spending during the crisis without much of an impact on life expectancy. The private funding of the system is very high as a result of the demise of public spending. Finally, pharma spending is significantly higher than expected for a country like Greece.
The Greek healthcare system is adequate in terms of infrastructure, it has more technology investment than necessary in certain areas and it remains unbalanced in terms of doctors, nurses, while it consumes more pharma than necessary.
It is imperative, before embarking on major structural reforms, to improve the system along a number of dimensions which will eventually be reflected on lower overall costs and lower private contributions:
Director, Internal Firm Services, Marketing & Communications, Athens, PwC Greece